Company: GANX
Filing Date: 2025-11-28
Form Type: 424B5
Source: 0001104659-25-116944
Chunk: 8

Company: Gain Therapeutics, Inc.
Filing Date: 2025-11-28
Form: 424B5
Chunk 8
---
>

TABLE OF CONTENTS

<div align='center'>Our Product Pipeline</div>

#### Corporate Information
We were incorporated under the laws of the state of Delaware on June 26, 2020 under the name Gain Therapeutics, Inc. Our principal executive offices are located at 4800 Montgomery Lane, Suite 220, Bethesda, MD 20814. Our telephone number is (301) 500-1556. Our website address is http://www.gaintherapeutics.com. Information contained on or accessible through our website is not incorporated by reference into this prospectus supplement, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus supplement.

<div align='center'>S-5</div>

TABLE OF CONTENTS

### THE OFFERING
The following summary contains basic information about our common stock and the offering and is not intended to be complete. It does not contain all of the information that may be important to you. For a more complete understanding of our common stock, you should read this prospectus supplement, the accompanying prospectus, and the documents referred to herein and therein.

Common stock offered by us

Shares of our common stock having an aggregate offering price of up to $35,530,980.56.

Common stock to be outstanding after this offering

Up to 49,777,683 shares (as more fully described in the notes following this table), assuming sales of 11,315,598 shares of our common stock in this offering at an assumed offering price of $3.14 per share, the closing sale price of our common stock on Nasdaq on November 26, 2024. The actual number of shares issued will vary depending on how many shares of our common stock we choose to sell and the prices at which such sales occur.

Manner of offering

“At the market offering” as defined in Rule 415(a)(4) under the Securities Act, that may be made from time to time through or to Oppenheimer, as sales agent or principal. See “ Plan of Distribution ” on page S-15.

Use of Proceeds

We currently intend to use the net proceeds from this offering, if any, for working capital and general corporate purposes. See “ Use of Proceeds ” on page S-12of this prospectus supplement.

Risk factors

Investing in our common stock involves significant risks. See “ Risk Factors ” on page S-7of this prospectus supplement, and under similar headings in other documents